Who are Inmazeb's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Inmazeb, Blenrep, Inmazeb, MARGENZA, UPLIZNA.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/atoltivimab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Inmazeb — Competitive Intelligence Brief

Inmazeb (ATOLTIVIMAB) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Immunology.

marketed Low affinity immunoglobulin gamma Fc region receptor III-A Immunology Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Inmazeb (ATOLTIVIMAB) — Regeneron. Inmazeb works by binding to the Ebola virus, preventing it from interacting with host cells and thereby reducing the severity of the disease.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Inmazeb TARGET	ATOLTIVIMAB	Regeneron	marketed		Low affinity immunoglobulin gamma Fc region receptor III-A	2020-01-01
Inmazeb	ODESIVIMAB	Regeneron	marketed		Low affinity immunoglobulin gamma Fc region receptor III-A	2020-01-01
Blenrep	Blenrep	Duke University	marketed		Low affinity immunoglobulin gamma Fc region receptor III-A, High affinity immunoglobulin gamma Fc receptor I, IgG receptor FcRn large subunit p51
Inmazeb	Inmazeb	ANRS, Emerging Infectious Diseases	marketed		Low affinity immunoglobulin gamma Fc region receptor III-A, Envelope glycoprotein
MARGENZA	MARGETUXIMAB-CMKB	MACROGENICS INC	marketed	HER2/neu Receptor Antagonist [EPC]	Low affinity immunoglobulin gamma Fc region receptor III-A, Receptor tyrosine-protein kinase erbB-2
UPLIZNA	INEBILIZUMAB-CDON	VIELA BIO	marketed	CD19-directed Cytolytic Antibody [EPC]	Low affinity immunoglobulin gamma Fc region receptor III-A, B-lymphocyte antigen CD19

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Inmazeb — Competitive Intelligence Brief. https://druglandscape.com/ci/atoltivimab. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab